Mobile website
Prompt Report
Gemcitabine chemotherapy combined with intratumoral injection of dendritic cells in treatment of mouse large lymphoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To investigate the effect of gemcitabine on myeloid derived suppressor cells (MDSC) in the spleen of B lymphoma cellbearing mice, and the therapeutic effect of gemcitabine combined with intratumoral injection of dendritic cells (DCs) in treatment of large B lymphoma. Methods: BALB/c mice were inoculated subcutaneously with B lymphoma A20 cells; large tumors were formed 30 d after inoculation. Gr1+CD11b+ MDSC proportion in the spleen was analyzed by flow cytometry before and after gemcitabine treatment. Splenic MDSC sorted by immunomagnetic beads was further treated with gemcitabine, and then the apoptosis of MDSC was examined by AnnexinV/PI staining. Tumor growth and survival time of A20 tumorbearing mice were observed after treatment with gemcitabine and intratumoral injection of DCs. Results: Splenic Gr1+CD11b+MDSC ratio in A20 cellbearing mice was 10 times higher than that in the normal mice. Gemcitabine induced apoptosis and necrosis of purified MDSC in vitro in a timedependent manner. The percentage of MDSC in the spleen of A20 tumorbearing mice was decreased after injection of a single dose of gemcitabine. Gemcitabine or intratumoral injection of DCs alone inhibited growth of tumor to a certain degree, with the mean survival periods of mice in the gemcitabine, DCs, and untreated groups being (48.8±3.6) d, (47.2±7.4) d, and (38.8±2.2) d, respectively. Gemcitabine chemotherapy combined with intratumoral DC injection resulted in continuous shrink of the tumors, and 60% of the mice survived for more than 90 d. Conclusion: Gemcitabine can effectively eliminate splenic MDSC in tumorbearing mice. Gemcitabine chemotherapy and DCs immunotherapy can work synergistically in the treatment of huge lymphoma. These results provide an experimental basis for the comprehensive chemotherapy and immunotherapy of relapsed or refractory lymphoma.
Keywords:
Project Supported:
Supported by the Key Project of Outstanding Medical Talents of Jiangsu Province (No. RC2007002)
Clc Number:
